MedTrace Logo

Biomarkers of Pancreatic Cancer and New Way to Detection

NCT04549064 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2021-08-23

No results posted yet for this study

Summary

Amphoteric regulatory protein (AREG), a member of epidermal growth factor (EGF) family, is expressed in many tumors.Our study confirmed that the expression of AREG in the serum of patients with pancreatic cancer is significantly higher than that of patients with benign pancreatic diseases and healthy people, which is expected to become a new early serum marker of pancreatic cancer. The serum concentration of AREG was detected by traditional ELISA and compared with CA-199, which was a conventional tumor marker of pancreatic cancer. Next, we compare the advantages of using sensor to detect AREG compared with ELISA.

Conditions

Interventions

DIAGNOSTIC_TEST

diagnosis of pancreatic cancer

Diagnosis of pancreatic cancer based on the concentration of serum biomarkers

Sponsors & Collaborators

  • West China Hospital

    collaborator OTHER

  • Xi'an Jiaotong University

    collaborator OTHER

  • First Affiliated Hospital Xi'an Jiaotong University

    lead OTHER

Principal Investigators

  • han su xia, professor · First Affiliated Hospital of Xian Jiaotong University

Eligibility

Min Age
20 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2021-12-01
Completion
2021-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04549064 on ClinicalTrials.gov